See the DrugPatentWatch profile for cosentyx

Based on the information available, there is limited data on the effects of Cosentyx (secukinumab) on child development. Cosentyx is a medication used to treat several conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, among others [1]. However, the clinical trials and studies mainly focus on its efficacy and safety in adult populations.

Novartis, the manufacturer of Cosentyx, has conducted clinical trials for secukinumab involving pediatric patients with plaque psoriasis. The trials are in different stages, with some completed and others ongoing or not yet recruiting [2]. While these studies will provide valuable information on the safety and efficacy of Cosentyx in children, they do not specifically investigate the drug's effects on child development.

DrugPatentWatch.com, a comprehensive database for pharmaceutical patents, lists Cosentyx and its related patents [3]. However, the website does not contain information on studies regarding Cosentyx's effects on child development.

In summary, while Cosentyx is used to treat conditions in adult and pediatric populations, there is limited data available on the drug's specific effects on child development. Clinical trials are ongoing to evaluate the safety and efficacy of Cosentyx in children with plaque psoriasis, but these studies do not focus on developmental aspects.

Sources:

1. Novartis. (2021). Cosentyx (secukinumab). <https://www.novartis.com/our-work/therapeutic-areas/immuno-dermatology/cosentyx>
2. ClinicalTrials.gov. (2021). Secukinumab in Pediatric Patients With Plaque Psoriasis. <https://clinicaltrials.gov/ct2/results?cond=Secukinumab+pediatric&term=&cntry=&state=&city=&dist=>
3. DrugPatentWatch.com. (2021). Cosentyx (secukinumab) Drug Patent Information. <https://www.drugpatentwatch.com/drugs/cosentyx-secukinumab>